Raphi Levy Sells 17,730 Shares of Alpha Tau Medical (NASDAQ:DRTS) Stock

August 13, 2026 by InsiderTrades.com

Key Points

Alpha Tau Medical CFO Raphi Levy sold 17,730 shares at an average price of $14, generating $248,220. The Rule 10b5-1 transaction reduced his direct holdings by 16.43% to 90,180 shares.
DRTS recently traded near its 52-week high, with a market capitalization of approximately $1.25 billion, but the company reported a quarterly loss of $0.50 per share, missing the $0.14 consensus estimate.
Analyst sentiment remains mixed but leans positive: five analysts rate the stock Buy, two Hold, and one Sell, producing a “Moderate Buy” consensus. HC Wainwright raised its target to $16 and reiterated Buy, while the average analyst target is $12.80.

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) CFO Raphi Levy sold 17,730 shares of the firm's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $14.00, for a total transaction of $248,220.00. Following the completion of the transaction, the chief financial officer directly owned 90,180 shares in the company, valued at approximately $1,262,520. This represents a 16.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

On Monday, July 6th, Raphi Levy sold 2,270 shares of Alpha Tau Medical stock. The shares were sold at an average price of $14.00, for a total transaction of $31,780.00.
On Thursday, July 2nd, Raphi Levy sold 17,873 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.00, for a total transaction of $232,349.00.
On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.02, for a total transaction of $27,693.54.
On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $12.00, for a total transaction of $240,000.00.
On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $11.00, for a total transaction of $220,000.00.
On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $9.55, for a total transaction of $167,125.00.
On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total transaction of $351,975.00.

Alpha Tau Medical Stock Down 2.8%

NASDAQ DRTS opened at $13.87 on Thursday. The business has a fifty day moving average price of $11.75 and a two-hundred day moving average price of $9.27. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.79 and a quick ratio of 7.79. Alpha Tau Medical Ltd. has a fifty-two week low of $3.00 and a fifty-two week high of $14.40. The stock has a market capitalization of $1.25 billion, a PE ratio of -13.34 and a beta of 1.17.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.36). The firm had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.14 million. Equities analysts expect that Alpha Tau Medical Ltd. will post -0.67 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on DRTS shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Alpha Tau Medical in a research report on Friday, July 17th. Piper Sandler increased their target price on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the stock a "neutral" rating in a report on Tuesday, May 19th. Benchmark restated a "buy" rating on shares of Alpha Tau Medical in a research note on Thursday, July 23rd. Zacks Research upgraded shares of Alpha Tau Medical from a "strong sell" rating to a "hold" rating in a research note on Monday, August 3rd. Finally, HC Wainwright lifted their price target on shares of Alpha Tau Medical from $15.00 to $16.00 and gave the company a "buy" rating in a report on Tuesday. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $12.80.

Check Out Our Latest Analysis on Alpha Tau Medical

Hedge Funds Weigh In On Alpha Tau Medical

Several large investors have recently bought and sold shares of DRTS. Trifecta Capital Advisors LLC acquired a new stake in shares of Alpha Tau Medical during the fourth quarter valued at about $48,000. Everhart Financial Group Inc. acquired a new position in shares of Alpha Tau Medical in the second quarter valued at approximately $126,000. Envestnet Asset Management Inc. acquired a new position in shares of Alpha Tau Medical in the third quarter valued at approximately $62,000. Principal Financial Group Inc. bought a new position in Alpha Tau Medical in the 1st quarter valued at approximately $132,000. Finally, Bank of America Corp DE raised its holdings in Alpha Tau Medical by 2,779.1% in the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company's stock valued at $101,000 after buying an additional 21,677 shares during the last quarter. 2.65% of the stock is currently owned by institutional investors.

Key Headlines Impacting Alpha Tau Medical

Here are the key news stories impacting Alpha Tau Medical this week:

Positive Sentiment: HC Wainwright raised its price target on Alpha Tau Medical to $16 from $15 and reiterated a “Buy” rating. The target implies approximately 15% upside from the referenced $13.87 price, providing a positive catalyst for DRTS. HC Wainwright raises Alpha Tau Medical price target
Positive Sentiment: Investor interest has helped push DRTS to a new 12-month high, with market coverage highlighting the potential for further appreciation under HC Wainwright’s bullish outlook. Alpha Tau Medical sets new 12-month high

About Alpha Tau Medical

(Get Free Report)

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.